Nivolumab Market Forecasts Indicate Robust Growth Driven by Advances in Cancer Immunotherapy and Increased Global Access to Care
15 févr. 2024 14h57 HE
|
Research and Markets
Dublin, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The "Nivolumab Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Recent advancements in cancer treatment and the...
Global Kidney Cancer Drugs Market Research Report 2023: Forecasts to 2027 & 2032 with Focus on Axitinib (Inlyta), Cabozantinib (cabometyx), and Pazopanib
13 mars 2023 08h53 HE
|
Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global kidney cancer drugs market will...
Global Kidney Cancer Drugs Market Report 2022-2026 & 2030 - Focus on Immunotherapy, Chemotherapy and Targeted Therapy
19 avr. 2022 04h48 HE
|
Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2022, Type, Product, End Users" report has been added to ResearchAndMarkets.com's offering. The global...
Kidney Cancer Drugs Industry Assessment and Recovery to 2030 - Insights on Drugs, Trends, Global Market Shares, Competitors, Strategies and More
04 févr. 2022 04h38 HE
|
Research and Markets
Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The...
Research Report on China's $400+ Million Sorafenib Market, 2021-2025
31 déc. 2021 05h38 HE
|
Research and Markets
Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Research Report on China's Sorafenib Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. According to the publisher's...
VG Life Sciences Inc. Progress Update Phase I Cancer Study
04 sept. 2014 08h07 HE
|
VG Life Sciences
SANTA BARBARA, Calif., Sept. 4, 2014 (GLOBE NEWSWIRE) -- VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces today an update to its physician-initiated IND phase I study to test...